Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

November 15, 2018

Janssen applies for expanded approval for IMBRUVICA in Europe

The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted two Type II variation applications to the European Medicines Agency (EMA) regarding approval for the expanded use of IMBRUVICA (ibrutinib).

Janssen applies for expanded approval for IMBRUVICA in Europe